Passive immunotherapy targeting amyloid-β reduces cerebral amyloid angiopathy and improves vascular reactivity

Brain

Volumn 139, Issue 2, 2016, Pages 563-577

  Bales, Kelly R ^a   O'Neill, Sharon M ^a   Pozdnyakov, Nikolay ^a   Pan, Feng ^a   Caouette, David ^a   Pi, Yeqing ^a   Wood, Kathleen M ^a   Volfson, Dmitri ^a   Cirrito, John R ^b   Han, Byung Hee ^b   Johnson, Andrew W ^b   Zipfel, Gregory J ^b   Samad, Tarek A ^a  

^a PFIZER INC   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer; amyloid ; CAA; vascular reactivity

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; PONEZUMAB; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; BRAIN BLOOD VESSEL; BRAIN INTERSTITIAL FLUID; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CIRCULATION; CEREBRAL AMYLOID ANGIOPATHY; DRUG EFFECTS; IMMUNOLOGY; MALE; METABOLISM; PASSIVE IMMUNIZATION; PHYSIOLOGY; PLAQUE, AMYLOID; PROCEDURES; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CEREBRAL AMYLOID ANGIOPATHY; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; IMMUNIZATION, PASSIVE; MALE; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 84959889919     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv313     Document Type: Article

References (63)

1. Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011; 69: 320-7
2. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 2005; 110: 345-59
3. Bates D, Maechler M, Bolker B, Walker S. lme4: Linear Mixed-effects Models Using Eigen and S4. R package version 1.1-0; 2013. http:// lme4.r-forge.r-project.org/
4. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-13
5. Burbach GJ, Vlachos A, Ghebremedhin E, Del Turco D, Coomaraswamy J, Staufenbiel M, et al. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. Neurobiol Aging 2007; 28: 202-12
6. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA 1999; 96: 14088-93
7. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003; 23: 8844-53
8. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002; 295: 2264-7
9. Dumas A, Dierksen GA, Gurol ME, Halpin A, Martinez-Ramirez S, Schwab K, et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol 2012; 72: 76-81
10. Freeman GB, Brown TP, Wallace K, Bales KR. Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. Curr Alzheimer Res 2012a; 9: 1059-68
11. Freeman GB, Lin JC, Pons J, Raha NM. 39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis 2012b; 28: 531-41
12. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. Cerebrovascular lesions induce transient beta-amyloid deposition. Brain 2011; 134(Pt 12): 3697-707
13. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-90
14. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gammasecretase inhibition. J Neurosci 2008; 28: 13542-50
15. Herzig MC, Van Nostrand WE, Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol 2006; 16: 40-54
16. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 2004; 7: 954-60
17. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274: 99-102
18. Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80: 844-66
19. Ishii K, Tamaoka A, Mizusawa H, Shoji S, Ohtake T, Fraser PE, et al. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997; 748: 250-2
20. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000; 6: 143-50
21. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159-70
22. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813-36
23. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007; 62: 229-34
24. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009; 72: 1230-5
25. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002; 61: 797-805
26. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005; 167: 527-43
27. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest: Tests for random and fixed effects for linear mixed effect models (lmer objects of lme4 package). R-Version:1.1-0; 2013. http://cran.r-project. org/web/packages/lmerTest/index.html
28. La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, et al. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol 2012; 421: 525-36
29. Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB, Jr et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, doseescalation study. Clin Neuropharmacol 2013; 36: 14-23
30. Lanz TA, Schachter JB. Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies. J Neurosci Methods 2008; 169: 16-22
31. Lenth, RV. lsmeans: least-squares means. R package version 2.11; 2014. http://CRAN.R-project.org/package=lsmeans
32. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O'Keefe G, et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010; 74: 487-93
33. Maat-Schieman M, Roos R, van Duinen S. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology 2005; 25: 288-97
34. Maia LF, Mackenzie IR, Feldman HH. Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci 2007; 257: 23-30
35. Mandybur TI. Cerebral amyloid angiopathy: the vascular pathology and complications. J Neuropathol Exp Neurol 1986; 45: 79-90
36. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774
37. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006; 65: 1012-21
38. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002; 23: 405-12
39. Nicholson C, Chen KC, Hrabetova S, Tao L. Diffusion of molecules in brain extracellular space: theory and experiment. Prog Brain Res 2000; 125: 129-54
40. Pan F, Gan WB. Two-photon imaging of dendritic spine development in the mouse cortex. Dev Neurobiol 2008; 68: 771-8
41. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, et al. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res 2003; 25: 642-51
42. Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates, 2nd edn. San Diego; Academic Press; 2001
43. Peca S, McCreary CR, Donaldson E, Kumarpillai G, Shobha N, Sanchez K, et al. Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 2013; 81: 1659-65
44. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379
45. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2014. http://www.R-project.org/
46. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathyassociated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25: 629-36
47. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003; 62: 885-98
48. Salloway S, Sperling R, Brashear HR. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 2014a; 370: 1460
49. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014b; 370: 322-33
50. Samaroo HD, Opsahl AC, Schreiber J, O'Neill SM, Marconi M, Qian J, et al. High throughput object-based image analysis of beta-amyloid plaques in human and transgenic mouse brain. J Neurosci Methods 2012; 204: 179-88
51. Smith EE, Vijayappa M, Lima F, Delgado P, Wendell L, Rosand J, et al. Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology 2008; 71: 1424-30
52. Sperling RA, Sollaway S, Brooks DJ, Tampieri D, Barakos J, Fox NC et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11: 241-49
53. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13
54. Tontsch U, Bauer HC. Isolation, characterization, and long-term cultivation of porcine and murine cerebral capillary endothelial cells. Microvasc Res 1989; 37: 148-61
55. Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener 2013; 8: 13
56. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 2009; 66: 245-9
57. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311-24
58. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. Stroke 1983; 14: 924-8
59. Walker LC. Animal models of cerebral beta-amyloid angiopathy. Brain Res Brain Res Rev 1997; 25: 70-84
60. Weller RO, Nicoll JA. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 2003; 25: 611-6
61. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006; 26: 5340-6
62. Yamaguchi H, Yamazaki T, Lemere CA, Frosch MP, Selkoe DJ. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 1992; 141: 249-59
63. Yang G, Pan F, Parkhurst CN, Grutzendler J, Gan WB. Thinned-skull cranial window technique for long-term imaging of the cortex in live mice. Nat Protoc 2010; 5: 201-8.